This company is dead in the water … outstanding shares bloated...

This company is dead in the water … outstanding shares bloated and diluted to the tune of about 1.2B (rounded) with a market capitalisation of just $30M (rounded). The former is the killer. It isn’t going to survive in the bio pharmaceutical shark infested ASX. And it's only at the first clinical trial. Another CR down the track and more share dilution. IMO, the only value is the IP, if at all and the hedge funds will get that.

Retail investors, this could be your ticket to a tax write off rather a profit take. The company intentions are admirable but hey man they’ve missed the boat and is a classic example of a company in the movie, “Margin Call”.